genedrive plc (AIM: GDR) expects to report total income of £1.4 million for the year ended 30 June 2026, up from around £1.0 million in FY25 and in line with
Genedrive technology showcased in Parliament
Genedrive plc (AIM: GDR) has highlighted comments from UK Health Minister Preet Kaur Gill MP, who cited rapid pharmacogenetic testing for antibiotic-induced hearing loss as a practical example of personalised
genedrive partners with Thermo Fisher on NHS testing
genedrive plc (AIM: GDR) has entered into a product development collaboration with Thermo Fisher Scientific to develop a high-throughput CYP2C19 pharmacogenetic test for deployment on Thermo Fisher’s QuantStudio™ 5 Dx
genedrive plc (LON: GDR) New interactive investor hub
genedrive plc launches new interactive investor hub
genedrive plc (AIM: GDR) Scotland national roll-out of Genedrive® MT-RNR1 ID Kit
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to note the recent media coverage of its Genedrive® MT-RNR1 ID Kit, which reduces the risk of
genedrive plc (AIM: GDR) MT-RNR1 ID Kit in Dublin’s Rotunda Hospital
Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital
Genedrive Shares Jump 22% on Talks Over £1 Million Shareholder Loan
Genedrive PLC (AIM: GDR) shares soared 22% to 1.04p after the diagnostics company confirmed it is in talks with major shareholder David Nugent regarding a potential £1 million loan to
genedrive plc (AIM: GDR) Comment re: Share Price Movement
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company’s share price on 13 August 2025 which it believes was connected to postings
genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds
Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
Genedrive PLC (AIM:GDR) received European regulatory approval
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care
Genedrive PLC (AIM:GDR) CYP2C19-ID Kit adopted for routine clinical use
North West Anglia Foundation NHS Trusts’ Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use
Genedrive PLC (AIM:GDR) Genedrive® CYP2C19-ID Kit performance published
Superior performance to laboratory test and alternative available point of care platforms